THE PUTATIVE REGENERATIVE CAPABILITY OF CELASTROL AND ITS NANOEMULSION ON OSTEOPOROTIC RATS EXPERIMENTALLY INDUCED BY OVARIECTOMY

Document Type : Original Article

Authors

1 oral biology department, faculty of dentistry, zagazig university

2 professor of oral biology Zagazig university

3 Faculty of Dentistry, Suez Canal University

4 Faculty of Pharmacy, Suez Canal University

Abstract

Introduction: Postmenopausal osteoporosis (PMOP) is the most common bone
disease in the developed world with serious public health concerns. Celastrol (CEL) has
been voted as one of the top five promising natural medicine molecules which may help
in PMOP management. Celastrol nanoemulsion (CTL-NE) was proved to improve the
oral bioavailability, therapeutic effects of CTL. Aim of the study: To detect and compare
the effect of CTL and CTL-NE on mandibular bone architecture and bone turnover
markers (BTMs) in ovariectomized (OVX) rats as a model of PMOP. Materials and
Methods: Two groups of sixty female rats; the OVX group and the sham group, were
assigned at random. The rats in each group were further separated into three equal
subgroups sixty days after OVX and sham operations. The rats in subgroup 1 were
not given any treatment, those in subgroup 2 were given CTL, and those in subgroup
3 were given CTL-NE for four weeks. At the end of the experiment, blood samples
were collected for biochemical analysis of bone turnover markers (BTMs), then the
rats were euthanized, and their lower jaws were prepared for light microscope (LM).
Results: Histological examination of OVX rats mandibular bone revealed compromised
bone architecture and significant increase in BTMs compared with the normal sham
ones. Interestingly OVX group showed notable improvement in bone microstructure
and marked decrease in BTMs upon celastrol administration, however, the superior
improvement was achieved in CTL-NE treated rats and these results were confirmed
histologically and biochemically. Conclusion: Systemic administration of CTL and
CTL-NE may be effective therapy for treatment of poor bone quality in OVX induced
osteoporosis, with privilege to CTL-NE therapy.

Keywords

Main Subjects

Dental Science Updates
Volume 6, Issue 2
September 2025
Pages 369-378

Files

Share

How to cite

Statistics